TITLE

Clinically significant outcomes in smoking cessation

AUTHOR(S)
Aubin, H-J.; Bobak, A.; Britton, J. R.; Oncken, C.; Billing Jr, C. B.; Gong, J.; Williams, K. E.; Reeves, K. R.
PUB. DATE
August 2008
SOURCE
Thorax;Aug2008, Vol. 63 Issue 8, p752
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A response by H-J. Aubin, A. Bobak, J. R. Britton and colleagues to a letter to the editor about their article "Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial" in a previous issue is presented.
ACCESSION #
34153279

 

Related Articles

  • Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field. Aubin, H-J.; Bobak, A.; Britton, J. H.; Oncken, C.; Billing Jr, C. B.; Gong, J.; Williams, K. E.; Reeves, K. R. // Thorax;Aug2008, Vol. 63 Issue 8, p752 

    A letter to the editor is presented in response to the article "Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial," by H-J. Audin, and colleagues in a previous issue.

  • Clinically significant outcomes in smoking cessation. Hiliman, T.; Rajakulasingam, K.; Bhowmik, A. // Thorax;Aug2008, Vol. 63 Issue 8, p752 

    A letter to the editor is presented in response to the article "Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial," by H-J. Audin, and colleagues in a previous issue.

  • The Importance of Systematic Reviews. Matthews, Debora; Sutherland, Susan // Journal of the Canadian Dental Association;Jul/Aug2001, Vol. 67 Issue 7, p366 

    A letter to the editor is presented in response to the article "Should the Use of Smoking Cessation Products Be Promoted by Dental Offices? An Evidence-Based Report," by Doug Brothwell in the March 2001 issue.

  • Response from Dr. Brothwell. Brothwell, Doug // Journal of the Canadian Dental Association;Jul/Aug2001, Vol. 67 Issue 7, p366 

    A response by Doctor Doug Brothwell to a letter to the editor about his article "Should the Use of Smoking Cessation Products Be Promoted by Dental Offices? An Evidence-Based Report" in the March 2001 issue is presented.

  • Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Fagerström, Karl Olov; Hughes, John R; Callas, Peter W. // Nicotine & Tobacco Research;Dec2002 Supplement 2, Vol. 4, p141 

    This study investigated the long term use of Eclipse, a cigarette-like device that heats rather than burns tobacco, and the Nicorette oral inhaler, a nicotine replacement product, in a group of smokers not interested in quitting smoking. Subjects were recruited from a previous four-week...

  • Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation. Aubin, H-J. // Drugs;2002 Supplement 2, Vol. 62 Issue 11, p45 

    Sustained-release bupropion (bupropion SR) was first launched in the US in 1997 as an aid to smoking cessation and has since been launched in many other countries. Adverse events associated with the use of bupropion SR at the recommended dosage of 150mg twice daily in clinical trials most...

  • Smoking hot minis.  // Drug Store News;6/7/2010, Vol. 32 Issue 7, p113 

    A preview of the Nicorette Mini Lozenge, a smaller smoking cessation lozenge, from GlaxoSmithKline is presented.

  • HEART HEALTH.  // Time;7/18/2011, Vol. 178 Issue 3, p17 

    Statistics are presented on the percentage increase in heart problems for smokers that utilized the smoking cessation drug Chantix when compared to nonusers.

  • HEART HEALTH.  // Time International (South Pacific Edition);7/18/2011, Vol. 178 Issue 3, p17 

    Statistics are presented on the percentage increase in heart problems for smokers that utilized the smoking cessation drug Chantix when compared to nonusers.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics